APA (7th ed.) Citation

Goyal, L., Al-Rajabi, R., Sahin, I., Subbiah, V., Vogel, A., Yarchoan, M., . . . Zalutskaya, A. (2025). 288eTiP A multicenter, open-label, first-in-human study of TYRA-430 in advanced hepatocellular carcinoma and other solid tumors with activating FGF/FGFR pathway aberrations (SURF431). Annals of Oncology, 36, S318. https://doi.org/10.1016/j.annonc.2025.08.716

Chicago Style (17th ed.) Citation

Goyal, L., et al. "288eTiP A Multicenter, Open-label, First-in-human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors with Activating FGF/FGFR Pathway Aberrations (SURF431)." Annals of Oncology 36 (2025): S318. https://doi.org/10.1016/j.annonc.2025.08.716.

MLA (9th ed.) Citation

Goyal, L., et al. "288eTiP A Multicenter, Open-label, First-in-human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors with Activating FGF/FGFR Pathway Aberrations (SURF431)." Annals of Oncology, vol. 36, 2025, p. S318, https://doi.org/10.1016/j.annonc.2025.08.716.